A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

This randomized phase III trial is studying gemcitabine hydrochloride, docetaxel, and
bevacizumab to see how well they work compared with gemcitabine hydrochloride, docetaxel, and
a placebo in treating patients with advanced or recurrent uterine leiomyosarcoma. Drugs used
in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether
gemcitabine hydrochloride and docetaxel are more effective when given with or without
bevacizumab in treating uterine leiomyosarcoma.